# Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin

> **NCT00552149** · PHASE2 · COMPLETED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 150 (actual)

## Conditions studied

- Advanced Biliary Cancer

## Interventions

- **DRUG:** Gemox, Cetuximab

## Key facts

- **NCT ID:** NCT00552149
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2012-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00552149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00552149, "Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00552149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*